Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02549339 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up
A Phase 3 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 383
- Enrollment target
NCT02549339 is a Phase 3 study that has completed, run by LEO Pharma. The registered enrollment target is 383 participants.
The verdict
NCT02549339, a Phase 3 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 383 participants
- Enrollment target
Study Summary
The objective of the trial is to compare the short term efficacy of LEO 43204 gel with vehicle gel in AK on face or chest when applied topically once daily for 3 consecutive days as field treatment
Interventions
- DRUG Vehicle gel
- DRUG LEO 43204 gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 383 participants |
| Start Date | 2015-11-13 |
| Est. Completion | 2017-08-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02549339
The ClinicalTrials.gov registry entry for NCT02549339 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 383 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle gel is the first listed.
NCT02549339 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02549339 about?
NCT02549339 is a clinical study titled "Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up". The objective of the trial is to compare the short term efficacy of LEO 43204 gel with vehicle gel in AK on face or chest when applied topically once daily for 3 consecutive days as field treatment
What is the current status of trial NCT02549339?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 383 participants. The study started on 2015-11-13. Estimated completion is 2017-08-10.
What interventions are being tested in trial NCT02549339?
The interventions under investigation include: Vehicle gel (DRUG), LEO 43204 gel (DRUG).
Who is sponsoring clinical trial NCT02549339?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.